Phase 3
N=40
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Bottom Line
View on ClinicalTrials.gov: NCT04857983 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Positive & Negative Symptom Scale Total (PANSSt) — 56.77; 54.24; 52.23; 49.29 score on a scale — p=0.004
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Memantine (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, San Diego
- Primary completion
- Mar 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Positive & Negative Symptom Scale Total (PANSSt) |
56.77; 54.24; 52.23; 49.29; 53.00; 48.47 | 0.004 sig |
| PRIMARY World Health Organization Disability Schedule (WHODAS 2.0) |
20.31; 23.06; 21.62; 24.94; 18.77; 23.65 | 0.129 |
| PRIMARY MATRICS Consensus Cognitive Battery Global Composite T-score (MCCB-C) |
36.38; 31.00; 38.46; 33.76; 42.23; 36.29 | 0.001 sig |
| SECONDARY Positive & Negative Symptom Scale (PANSS) - Positive Symptom Subscale |
14.08; 13.41; 14.31; 11.29; 14.15; 12.18 | 0.192 |
| SECONDARY Positive & Negative Symptom Scale (PANSS) - Negative Symptom Subscale |
13.62; 13.65; 12.07; 12.76; 12.08; 11.82 | 0.016 sig |
| SECONDARY Psychotic Symptoms - PSYRATS Hallucination Subscale |
12.62; 7.35; 14.92; 6.24; 13.23; 7.18 | 0.786 |
| SECONDARY Manic Symptoms - Young Mania Rating Scale |
3.38; 2.53; 3.54; 2.53; 4.62; 2.65 | 0.536 |
| SECONDARY Current Depressive Symptoms - PHQ-9 |
6.85; 8.18; 5.69; 6.29; 6.62; 6.65 | 0.298 |
Summary
Treatment of schizophrenia currently includes antipsychotic medications and cognitive therapies which improve some symptoms, but do not sufficiently restore cognitive functioning or reduce psychosocial disability. We hypothesize that medications that specifically target sensory information processing deficits, rather than psychotic symptoms per se, will significantly enhance the benefits of a sensory-based targeted cognitive training (TCT) intervention in patients with schizophrenia. We will complete a randomized, double-blind clinical trial to: 1) confirm that the drug memantine augments TCT learning; 2) determine whether memantine enhances the clinical benefits from a full 30 session course of TCT vs. TCT plus placebo in antipsychotic- medicated schizophrenia patients, and 3) determine if memantine's enhancement of TCT is most effective in biomarker-defined subgroups of patients.
Eligibility Criteria
Inclusion Criteria
- DSM-IV diagnosis of schizophrenia or schizoaffective disorder
- Written informed consent to participate in the study
- Age 18-65
- Absence of dementia or mental retardation
- Urine toxicology negative for recreational drugs
- Fluent and literate in English
Exclusion Criteria
- Meets DSM-IV criteria for current substance abuse or dependence and has been substance abstinent for less than 30 days
- A history of traumatic brain injury
- Auditory or visual impairments severe enough to prevent study participation
- Under conservatorship (determined by Anasazi)
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT04857983). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.